Company news
Fortress Biotech, Inc. (NASDAQ:FBIO) news
Every Fortress Biotech, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing
July 28, 2026
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
July 27, 2026
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
May 18, 2026
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
April 21, 2026
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
March 31, 2026
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
March 30, 2026
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
March 25, 2026
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
March 18, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
February 23, 2026
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 ...
February 23, 2026
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher f...
February 23, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease ...
January 14, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatme...
January 13, 2026
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
December 15, 2025
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora o...
December 10, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 14, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 14, 2025
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 12, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 6, 2025
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
November 5, 2025
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Cl...
October 24, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Doti...
October 21, 2025
Journey Medical Corporation to Participate in October 2025 Investor Conferences
October 8, 2025
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
October 1, 2025
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
October 1, 2025
Journey Medical Corporation to Participate in September 2025 Investor Conferences
September 3, 2025
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Journey Medical Corporation to Present at the Emerging Growth Conference
August 18, 2025
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 12, 2025
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
August 7, 2025
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
August 5, 2025
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
July 14, 2025
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
July 7, 2025
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
June 24, 2025
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 202...
June 20, 2025
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
June 9, 2025
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
May 30, 2025
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 15, 2025
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 14, 2025
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
May 13, 2025
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 7, 2025
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
April 1, 2025
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
March 31, 2025
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 m...
March 24, 2025
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
March 19, 2025